Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:DERM NASDAQ:FBRX NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.84$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsDERMJourney Medical$7.21-4.5%$7.27$3.54▼$8.90$189.70M0.7997,510 shs155,826 shsFBRXForte Biosciences$15.27+0.9%$12.21$4.11▼$28.68$189.85M3.03106,293 shs76,045 shsTARAProtara Therapeutics$5.22-7.0%$3.55$1.62▼$10.48$201.40M1.53797,858 shs745,681 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.91%+3.06%+12.85%+5.76%+1.51%DERMJourney Medical0.00%-1.64%-1.90%+0.84%+21.18%FBRXForte Biosciences0.00%-1.42%+45.98%+44.74%+205.40%TARAProtara Therapeutics0.00%+5.24%+63.13%+71.15%+208.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.84$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsDERMJourney Medical$7.21-4.5%$7.27$3.54▼$8.90$189.70M0.7997,510 shs155,826 shsFBRXForte Biosciences$15.27+0.9%$12.21$4.11▼$28.68$189.85M3.03106,293 shs76,045 shsTARAProtara Therapeutics$5.22-7.0%$3.55$1.62▼$10.48$201.40M1.53797,858 shs745,681 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.91%+3.06%+12.85%+5.76%+1.51%DERMJourney Medical0.00%-1.64%-1.90%+0.84%+21.18%FBRXForte Biosciences0.00%-1.42%+45.98%+44.74%+205.40%TARAProtara Therapeutics0.00%+5.24%+63.13%+71.15%+208.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/ADERMJourney Medical 2.20Hold$12.1768.75% UpsideFBRXForte Biosciences 2.50Moderate Buy$68.00345.32% UpsideTARAProtara Therapeutics 2.86Moderate Buy$19.60275.48% UpsideCurrent Analyst Ratings BreakdownLatest AADI, DERM, FBRX, and TARA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025DERMJourney MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TARAProtara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DERMJourney MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TARAProtara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/25/2025DERMJourney MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025DERMJourney MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.00(Data available from 10/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.99N/AN/A$4.29 per share0.47DERMJourney Medical$56.13M3.38N/AN/A$0.91 per share7.92FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)DERMJourney Medical-$14.67M-$0.38N/AN/AN/A-15.49%-48.69%-11.26%11/11/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.62N/AN/AN/AN/A-36.87%-33.85%11/11/2025 (Estimated)Latest AADI, DERM, FBRX, and TARA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/12/2025Q2 2025DERMJourney Medical-$0.07-$0.16-$0.09-$0.16$14.93 million$15.01 million8/11/2025Q2 2025TARAProtara Therapeutics-$0.43-$0.35+$0.08-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54DERMJourney Medical1.111.270.95FBRXForte BiosciencesN/A11.7411.74TARAProtara TherapeuticsN/A12.8112.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%DERMJourney Medical7.25%FBRXForte Biosciences77.63%TARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%DERMJourney Medical15.03%FBRXForte Biosciences5.90%TARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableDERMJourney Medical9026.31 million22.36 millionN/AFBRXForte Biosciences512.43 million11.70 millionOptionableTARAProtara Therapeutics3038.58 million35.34 millionOptionableAADI, DERM, FBRX, and TARA HeadlinesRecent News About These CompaniesWeiss Ratings Reaffirms Sell (D-) Rating for Protara Therapeutics (NASDAQ:TARA)October 9 at 2:29 AM | americanbankingnews.comProtara Therapeutics' (TARA) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 9 at 2:26 AM | marketbeat.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from AnalystsOctober 8, 2025 | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 8, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2025 | globenewswire.comA Fresh Look at Protara Therapeutics (TARA) Valuation After Joining the S&P Global BMI IndexSeptember 24, 2025 | finance.yahoo.comWhat Protara Therapeutics (TARA)'s S&P Global BMI Inclusion Means For ShareholdersSeptember 22, 2025 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME)September 21, 2025 | theglobeandmail.comIdentifying Undervalued and Overlooked Assets to Address Unmet Patient NeedsSeptember 15, 2025 | fiercebiotech.comFProtara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Buy" by BrokeragesSeptember 15, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comProtara Therapeutics to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comWe're Not Very Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn RateAugust 13, 2025 | finance.yahoo.comProtara Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comProtara Beats Q2 Loss EstimatesAugust 11, 2025 | aol.comAProtara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateAugust 11, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAADI, DERM, FBRX, and TARA Company DescriptionsAadi Bioscience NASDAQ:AADI$2.02 -0.15 (-6.91%) As of 10/10/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Journey Medical NASDAQ:DERM$7.21 -0.34 (-4.50%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$7.22 +0.01 (+0.21%) As of 10/10/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Forte Biosciences NASDAQ:FBRX$15.27 +0.13 (+0.86%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$15.12 -0.15 (-0.98%) As of 10/10/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Protara Therapeutics NASDAQ:TARA$5.22 -0.39 (-6.95%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$5.36 +0.14 (+2.68%) As of 10/10/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
